A new drug provides a glimmer of hope for those of us with PKD: The Otsuka Pharmaceutical Co. announced on April 12, 2013 that the U.S. Food and Drug Administration (FDA) has accepted their new drug application for the potential use of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD), the disease I inherited from my father.
A New England Journal of Medicine study reports that tolvaptan slows the enlargement of cystic kidneys while also slowing the loss of kidney function–both by about 50%. The FDA’s target action date for Otsuka’s tolvaptan application is September 1, 2013. If approved, tolvaptan would become the first pharmaceutical therapy for patients with ADPKD.
My kidney function has crossed the border of stage 4 to stage 5, aka end-stage kidney failure. Last year my GFr (common measure of kidney function) fell from 50 to about 12, whereas it took 14 years for me to drift from 70 to 50. My situation is now urgent with the wait list for a non-living donor 4–7 years.
Because I am in end-stage kidney failure, I urgently need a living kidney donor. If you have type A or O blood, we may be a direct match, but it doesn’t matter if we’re a direct match or not–read on. Continue reading
What? That’s right.
In the last month there have been a number of newspaper articles and television news stories about this. On September 20, 2012 the New York Times said that during 2011 “2,644 of the 14,784 kidneys recovered were discarded, or nearly 18 percent, according to the United Network for Organ Sharing.”
Against this backdrop, my ongoing plea: I need someone to help me by becoming my kidney donor. (Follow this link to learn how.) Continue reading